secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-08-25T20:06:36+00:00
Accession:  0001628280-26-058864
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma gets FDA approval for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma
--------------------------------------------------------------------------------

- FDA approved Ziihera (zanidatamab-hrii) plus Tevimbra (tislelizumab-jsgr) and chemo for all HER2+ GEA (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status.
- Second approval: Ziihera plus chemo for HER2+ IHC 3+ GEA; based on Phase 3 HERIZON-GEA-01 trial.
- Trial showed 35% PFS risk reduction (12.4 vs 8.1 months) and 28% OS risk reduction (26.4 vs 19.2 months) vs trastuzumab plus chemo.
- Jazz hosts investor webcast Aug 25, 4:30pm ET; Ziihera is first bispecific HER2-targeted antibody plus PD-1 inhibitor approved in this setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/0001628280-26-058864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-058864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer